Statement of Changes in Beneficial Ownership (4)
March 07 2018 - 6:26PM
Edgar (US Regulatory)
|
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Wilderotter Mary Agnes
|
2. Issuer Name
and
Ticker or Trading Symbol
Juno Therapeutics, Inc.
[
JUNO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O 400 DEXTER AVENUE NORTH, SUITE 1200
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/5/2018
|
|
(Street)
SEATTLE, WA 98109
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Director Stock Option (Right to Buy)
|
$8.72
|
3/5/2018
(1)
|
|
D
|
|
|
75000
|
(2)
|
11/3/2024
|
Common Stock
|
75000
|
$78.28
(2)
|
0
|
D
|
|
|
Director Stock Option (Right to Buy)
|
$60.00
|
3/5/2018
(1)
|
|
D
|
|
|
12000
|
(2)
|
6/11/2025
|
Common Stock
|
12000
|
$27.00
(2)
|
0
|
D
|
|
|
Director Stock Option (Right to Buy)
|
$42.40
|
3/5/2018
(1)
|
|
D
|
|
|
12000
|
(2)
|
6/16/2026
|
Common Stock
|
12000
|
$44.60
(2)
|
0
|
D
|
|
|
Director Stock Option (Right to Buy)
|
$23.29
|
3/5/2018
(1)
|
|
D
|
|
|
12000
|
(2)
|
6/15/2027
|
Common Stock
|
12000
|
$63.71
(2)
|
0
|
D
|
|
|
Explanation of Responses:
|
|
(1)
|
On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
|
|
(2)
|
In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Wilderotter Mary Agnes
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE, WA 98109
|
X
|
|
|
|
Signatures
|
|
/s/ Zachary D. Hale, attorney-in-fact
|
|
3/7/2018
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Oct 2024 to Nov 2024
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Nov 2023 to Nov 2024
